VIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 2025
13. Januar 2025 09:00 ET
|
VIVUS LLC
CAMPBELL, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing...
VIVUS and UpScriptHealth Announce Launch of ChooseQ.online for Access to Advanced Weight Management Solutions
30. Oktober 2024 09:00 ET
|
VIVUS LLC
Collaborative telehealth platform will provide patients with immediate access to QSYMIA®, a chronic weight loss medication, enhancing their healthcare journey CAMPBELL, Calif., Oct. 30, 2024 ...
VIVUS Shares Significant Regulatory Update on QSYMIA®
28. Oktober 2024 09:30 ET
|
VIVUS LLC
- Postmarketing requirement fulfilled based on data demonstrating QYSMIA® reduces blood pressure - CAMPBELL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- VIVUS announced today that the U.S. Food and...
VIVUS Announces Label Update for QSYMIA®
23. Oktober 2024 09:00 ET
|
VIVUS LLC
– QSYMIA® is the leading once-daily oral branded, weight-management medication – – First head-to-head randomized placebo-controlled study of QSYMIA® and phentermine demonstrating reductions in...
VIVUS Announces Commercialization of QSIVA® in Sweden, Denmark, Finland, Iceland, Norway, and Poland
07. Oktober 2024 09:00 ET
|
VIVUS LLC
AMSTERDAM, Oct. 07, 2024 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, today announced the availability of QSIVA® (phentermine and topiramate modified-release) in Sweden, Denmark,...
Clinical Data Published at ASCO Support the Potential of VIVUS’ PANCREAZE® to Stabilize Weight and Improve Gastrointestinal Outputs in Patients with Pancreatic Cancer
30. Mai 2024 09:00 ET
|
VIVUS LLC
CAMPBELL, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing...
VIVUS Announces it will Provide Telehealth to Patients through an Enhanced 'Engage' Program in Collaboration with UpScriptHealth
22. April 2024 09:00 ET
|
VIVUS LLC
Collaboration will deliver a seamless telehealth experience, providing patients with immediate access to QSYMIA®, a chronic weight loss medication, enhancing their healthcare journey CAMPBELL,...
VIVUS Provides Update on Pipeline and Program Milestones
08. Januar 2024 09:00 ET
|
VIVUS LLC
CAMPBELL, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing...
New Clinical Data Demonstrate that QSYMIA®, the Leading Once-Daily Oral Weight-Management Medication, Reduces Blood Pressure
28. November 2023 09:00 ET
|
VIVUS LLC
CAMPBELL, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing...
VIVUS’ QSIVA in Combination with a Digital Lifestyle Intervention Leads to Significant Weight Loss and Decreased Cardiovascular Risk in Patients with Obesity
17. Mai 2023 03:30 ET
|
VIVUS LLC
— Poster presented at the 30th European Congress on Obesity (ECO 2023) shows addition of QSIVA provides benefits compared with Digital Lifestyle Intervention (DLI) alone in improving health outcomes...